OrsoBio raises $60m to advance treatment for obesity
OrsoBio has raised $60m in Series A financing to advance its metabolic portfolio for the treatment of obesity and associated disorders.
Stay updated with breaking news from Edd Fleming. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OrsoBio has raised $60m in Series A financing to advance its metabolic portfolio for the treatment of obesity and associated disorders.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Also 23andMe names Dr. Joseph R. Aaron as its next chief scientific officer.